Clinically, it has been reported that the mutation rate of p53 is 20% in primary castration-naive prostate cancer; 37% in metastatic castration-naive prostate cancer; and 73% in metastatic castration -resistant prostate cancer. This evidence concerns the gene TP53 and prostate carcinoma.